Our data demonstrate that ALDH3A1 increases cisplatin resistance in HNSCC and suggest that targeting this enzyme with a novel isozyme-specific inhibitor is a potentially viable treatment strategy. This evidence concerns the gene ALDH3A1 and head and neck squamous cell carcinoma.